Treatment with Sofosbuvir ameliorates disease outcomes of adult YFV-infected A129<sup>-/-</sup> mice.
<p>A129<sup>-/-</sup> mice were infected with 4x10<sup>2</sup> PFU of low passage clinical isolate of YFV by intravenous route. A-E) Viral loads from serum (A), liver (B), spleen (C), kidneys (D), and brain (E) assessed by plaque assay. Results are shown as median f Log<sub>10</sub> PFU equivalents per mL or g. F) Total and differential cell counts in blood were represented as number of differential cell counts (leukocytes, mononuclear cells and neutrophils) normalized to % of total cells counts. G) Hepatic transaminase levels of ALT were measured in serum of MOCK and YFV-infected mice at days 3 and 6 p.i. Results are shown as ALT (U/L) of serum. H) Histopathological score of liver tissue sections. I) Representative of hepatic damage and Hematoxylin & Eosin staining of liver sections of control and YFV-infected mice three days after infection (Scale Bar—100 μm). The images presented are representative animals on the third day of infection. Four animals per group were assayed. * for p<0.05 when compared to MOCK. # for p< 0.05 when compared to YFV.</p
Biochemistry, Medicine, Microbiology, Pharmacology, Biotechnology, Immunology, Cancer, Science Policy, Mental Health, Infectious Diseases, Plant Biology, Virology, Biological Sciences not elsewhere classified, Chemical Sciences not elsewhere classified, Yellow fever virus, weight loss, nucleotide binding, Flaviviridae family, EC 50 values, Swiss mice, YFV outbreaks, DENV, HCV, ZIKV, Other Flaviviruses, adult type, vivo Yellow fever virus, health emergencies, wild-type strains, sylvatic areas, acid residues, lethality rates, hepatitis C virus, Sofosbuvir, interferon receptor knockout mice, Yellow fever, YFV RNA polymerase, hepatoma cells, safety profile, sofosbuvir docks
DOI identifier: 10.1371/journal.pntd.0007072.g009
Sorry, we are unable to provide the full text but you may find it at the